| Developers: | Biocad |
The main articles are:
2024: Inclusion in the VED list
The Commission of the Ministry of Health included the original drug "Nurdati," developed by scientists of the biotechnological company BIOCAD, in the list of vital and essential drugs (VED). This solution opens up access to innovative therapies for more than 550 patients. Biocad announced this on August 23, 2024.
Nurdati is a monoclonal antibody drug created to treat patients with melanoma, including cases with metastases. The drug was developed and manufactured completely in Russia, the biotechnological company BIOCAD invested more than 1.4 billion rubles in its development.
 | The inclusion of an original domestic drug in VED allows for stable access to innovative therapy without the risk of interruptions, which is especially important for maintaining their health and ability to work. noted N.P. Dronov, Chairman of the Coordination Council of the MOD "Movement Against Cancer," member of the Council of Public Organizations for the Protection of Patients' Rights under the Ministry of Health of Russia.
|  |
The efficacy of Nurdati has been evaluated in clinical trials. The results of the comparative study, published in the journal Modern Oncology 2, show that Nurdati (a combination of nurulimab and prolgolimab) with continued prolgolimab therapy is superior to prolgolimab monotherapy in patients with unresectable or metastatic melanoma.
The number of potential patients who can receive treatment at 100% security is more than 12 thousand patients. The clinical study showed a stable effect of the drug in patients with unresectable and metastatic stage III-IV melanoma. Additionally, after the Nurdati course, the patient receives an average of 16 injections of Forteca (Prolgolimab), which is also included in the clinical guidelines.
The inclusion of the Russian drug in the VED list corresponds to the course of development of national priorities aimed, countries among other things, at increasing the availability of advanced medicines for Russian patients.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |